Metanefrine

Metanefrine is a sympathomimetic amine drug that acts as a non-selective beta-adrenergic receptor agonist. It is primarily used as a decongestant and bronchodilator, particularly in the treatment of asthma and chronic obstructive pulmonary disease (COPD). Metanefrine works by stimulating beta-adrenergic receptors in the smooth muscle of the airways, leading to relaxation and dilation of the bronchioles, which improves airflow and reduces symptoms such as wheezing and shortness of breath.

Metanefrine is available in various forms, including tablets, capsules, and inhalers. It is often prescribed as a short-term treatment for acute exacerbations of asthma and COPD. The drug is generally well-tolerated, but like other sympathomimetic amines, it can cause side effects such as tremors, palpitations, and increased heart rate. Prolonged use or high doses can lead to more serious side effects, including hypertension and cardiac arrhythmias.

Metanefrine is a controlled substance in many countries due to its potential for abuse and dependence. It is classified as a Schedule IV drug in the United States, which means it has a low potential for abuse relative to drugs in Schedule III. The drug should be used under medical supervision to minimize the risk of adverse effects and ensure appropriate dosing.

Metanefrine is not typically used as a first-line treatment for asthma or COPD, as there are other medications that are generally considered safer and more effective. However, it can be a useful option in certain situations, such as when other treatments are ineffective or when a rapid onset of action is required. As with any medication, the use of metanefrine should be carefully considered and monitored by a healthcare professional.